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Abstract: Glioblastoma multiforme (GBM) is the most common malignant primary brain 
tumor in adults and carries the poorest prognosis. Despite recent progress in molecular biology, 
neuro-imaging and neuro-surgical care, the management of patients with GBM continues to 
harbor significant challenges. Survival after diagnosis is poor even with the most aggressive 
approach using multimodality therapy. Although the etiology of malignant gliomas is not known, 
the dependency of tumor growth on angiogenesis has identified this pathway as a promising 
therapeutic target. Bevacizumab was the first antiangiogenic therapy approved for use in cancer 
and received accelerated Food and Drug Administration approval for the treatment of recurrent 
GBM in 2009, the first new drug for this disease in over a decade. This review describes the 
rationale behind the treatment of GBM with bevacizumab. The pharmacology, efficacy, safety 
and tolerability of bevacizumab will also be reviewed.
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Introduction
Cancers of the brain and nervous system are relatively rare. Glioblastoma multiforme 
(GBM) continues to be the most common and lethal malignant primary brain tumor 
in adults.1 The exact pathogenesis thus far has remained elusive, and most occur in a 
sporadic fashion.2–7 Rarely they occur in the setting of hereditary syndromes.8 Despite 
an aggressive multimodal approach, the median survival time after diagnosis is approxi-
mately a year with population-based studies demonstrating even lower median survival 
rates.9,10 Surgery allows histological diagnosis and can provide relief for neurological 
deficits related to mass effect. Surgery, however, is not curative due to the infiltrative 
nature of the disease. While only retrospective data are available to evaluate survival 
benefit, extent of resection correlates with better prognosis.11–13 Radiation therapy has 
been the mainstay treatment for GBM for decades extending median survival to about 
9 months versus a median survival of 3 months with no therapy.14–18 The role of chemo-
therapy in gliomas has historically been disappointing, with adjuvant therapy extending 
longer-term survival in the minority of GBM patients.16,17,19 This is in contrast to the 
more chemosensitive oligodendrogliomas harboring 1p/19q deletions.20 Chemotherapy 
as standard of care for GBM was only recently established in 2005, when Stupp et al 
demonstrated that daily temozolomide (TMZ) combined with radiation followed by 6 
months of adjuvant monthly cycle TMZ increased median survival by 3 months when 
compared to radiotherapy alone, and increased 2-year survival from 10% to 26%.21 Once 
disease progression occurs, available salvage chemotherapies are usually unsuccessful, 
demonstrating a 6-month progression-free survival (PFS-6) of only 15%.22OncoTargets and Therapy 2010:3 28
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Because of its poor prognosis with current multimodality 
treatment, a concerted effort is underway to develop new and 
novel therapeutic strategies that will increase survival and 
quality of life in patients with GBM. There has been prog-
ress in elucidating the molecular changes that underlie the 
pathogenesis of GBM. GBMs are hypervascular in nature and 
growth has been shown to be angiogenesis-dependent.23,24 
Bevacizumab is a humanized monoclonal antibody against 
vascular endothelial growth factor (VEGF) and has been 
shown to be an extremely potent inhibitor of angiogenesis. 
Based on an improved response rate compared to that of 
historical controls, bevacizumab (Avastin®; Genentech, San 
Francisco, CA, USA) received accelerated approval by the 
Food and Drug Administration (FDA) for recurrent GBM 
in May 2009, thereby becoming the first new drug labeled 
for gliomas in over a decade. We will review the role of 
VEGF pathways in glioma angiogenesis and the rationale 
for bevacizumab in this disease.
Angiogenesis in brain tumors
For tumors to attain a size beyond a few millimeters requires 
a process known as angiogenesis.25,26 Angiogenesis is a 
physiological process that depends on a well orchestrated 
balance of angiogenic factors and inhibitors that control the 
growth of microvessel sprouts via migration and proliferation 
of endothelial cells.27 When dysregulation of this process 
occurs, it may provide a suitable milieu for the initiation 
and maintenance of certain chronic disease states such pso-
riasis,28 ocular neovascularization29 and atherosclerosis.30 In 
addition, pathological angiogenesis has been shown to be 
a hallmark of certain tumor types such as GBM, colorectal 
carcinoma, breast and renal cell carcinomas.31 Tumor-
associated neo-vascularization differs from physiological 
angiogenesis, characterized by a substantial increase in the 
proliferation activity of endothelial cells that are structurally 
“leaky”.32 Tipping the scales in favor of a proangiogenic 
state requires upregulation of factors such as VEGF-A, 
platelet-derived growth factor (PDGF) and basic fibroblast 
growth factor (bFGF2).33–35 Additional pathways implicated 
in tumor angiogenesis are angiopoietin and Notch.36 Enzymes 
such as metalloproteinase and serine proteinase have been 
shown to be involved in the induction and suppression of 
angiogenesis by degrading the extracellular matrix.37 These 
have all been identified as possible substrates for therapeutic 
intervention.
Tissue hypoxia resulting from a tumor’s fast exponen-
tial growth has been a well-defined trigger of angiogenesis 
in solid tumors and manifests downstream by a number 
of inducible proangiogenic molecular changes. One such 
example involves hypoxia-inducible factor-1, a transcrip-
tion factor that regulates the expression of many angiogen-
esis- and glucose metabolism-related genes and in addition 
activates the transcription of VEGF in malignant gliomas.38,39 
VEGF mRNA expression, as well as VEGF receptor expres-
sion, are well documented hypoxic induced changes in 
malignant gliomas.40
Various chemokines and mitogens that promote angio-
genesis have been shown to be produced by both primary and 
recurrent gliomas and include basic fibroblast growth factor,41 
interleukin-8 (CXCL8),42,43 CXCL12,44 and hepatocyte 
growth factor/scatter factor.43 Neurotrophins and their cor-
responding receptors, which primarily mediate their effects 
via the receptor kinases TrkA-C, have been shown to support 
endothelial cell survival and proliferation as well as neuronal 
proliferation, differentiation and synaptogenesis.45–48 Other 
mechanisms include endothelial-cell spread and migration 
in response to certain growth factors mediated by certain 
integrins,49 as well as signaling via stem cell factor and its 
receptor c-Kit pathway, which is thought to be central in 
inducing tumor-based angiogenesis.50
VEGF-mediated angiogenesis
The first observations of the increased vascular nature of 
brain tumors were made by Rudolf Virchow during the 
nineteenth century.26 Later, based upon the concept that 
tumor angiogenesis was mediated by diffusible factors 
produced by tumor cells, Folkman proposed that inhibition 
of angiogenesis would be a reasonable strategy to treat 
cancer and initiated the isolation of tumor angiogenesis 
factors.26 In 1983, Senger et al reported the partial purifica-
tion of vascular permeability factor (VPF), a protein that 
induced vascular leakage in the skin.51 In 1989, Ferrara 
et al isolated VEGF, an endothelial-cell-specific mitogen.52 
The proteins VEGF and VPF were shown to be one and the 
same molecule by the work of Connolly et al.53 VEGF and 
its signaling are important mediators of glioma-induced 
angiogenesis.
The human VEGF gene has been located to chromosome 
6p21.3.52,54,55 VEGF has been described as a basic, heparin-
binding, homodimeric glycoprotein. There are at least 
five VEGF glycoproteins (VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E) and placental growth-factors PIGF-1 
and PlGF-2 that belong within the same family. VEGF-A 
binding is the dominant mediator of pro-angiogenic signaling 
in human cancers and VEGF-A has different isoforms that 
are generated by alternate splicing. The VEGF glycoprotein OncoTargets and Therapy 2010:3 29
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acts in a number of ways to mediate the above-described 
effects. It binds two related receptor tyrosine kinases (RTK), 
named Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2)56,57 and 
interacts with a family of co-receptors known as neuropilins. 
By binding to these receptors, VEGF (and in a similar manner 
PDGF),58 induces homodimerization of two receptor subunits 
and thereby induces autophosphorylation of the intracellular 
tyrosine kinase domains.56,57,59 This phenomenon then leads to 
downstream signal transduction. VEGFR-3 has been shown 
to mediate the mitogenic and survival activity of VEGF via 
the phosphatidylinositol-3 kinase/phosphatase and tensin 
homologue/Akt/mammalian target of rapamycin (PtdIns3K/
PTEN/Akt/mTOR) pathway,60 the PLCγ61 and Ras/Raf/ 
mitogen-activated protein kinases MAPK p44/42.62–64
The Notch transmembrane protein and its ligand Jagged/
Delta are activated by VEGF signaling and tend to suppress 
angiogenesis. Blocking the Delta-like ligand 4 has been 
shown to increase sprouting in a glioma model, paradoxically 
minimizing tumor growth. Notch signaling seems essential 
to the negative feedback control of VEGF signaling in 
brain tumors.65–67 In recent years another molecule known 
as γ-secretase, a presenilin-dependant protease complex 
also implicated in the pathogenesis of Alzheimer’s disease, 
has been identified as a significant player in the induction 
and maintenance of tumor-based angiogenesis by cleaving 
the Notch molecule.68,69 VEGFR1 and insulin-like growth 
factor-1, which are receptors involved in promoting angio-
genesis in GBM, have also been shown to be cleaved by 
γ-secretase.70,71
VEGF has been shown to be a significant regulator of 
embryonal and physiological and pathological angiogenesis, 
including that of tumor growth.72 In vitro studies have shown 
that VEGF can promote the growth of vascular endothelial 
cells derived from both blood vessels and lymphatic vessels,73 
act as a survival factor for endothelial cells,63,74 induce vasodi-
latation,75 promote inflammation through vascular leakage,51 
induce chemotaxis of endothelial cells,76 increase proteolytic 
enzyme expression and hence promote extracellular matrix 
degradation,76 promote monocyte activation and chemotaxis,76 
and inhibit the maturation of antigen-presenting dendritic 
cells.77 A number of studies have shown that in addition to 
endothelial cells VEGF exerts a mitogenic and survival effect 
on nonendothelial cell types such as nerve cells.78
The efficacy of antiangiogenic agents has been dem-
onstrated in preclinical xenograft brain tumor models.80,81 
Calabrese et al demonstrated that self-renewal capacity of 
brain tumor cells were maintained by endothelial factors 
and modulation of this “vascular niche” with antiangiogenic 
agents decreased tumor growth.79 Because VEGF plays such 
a significant role in the process of angiogenesis, development 
of therapeutic interventions targeting VEGF and VEGFR sig-
naling is rational. The use of such agents to treat brain tumors 
has been increasing and to date there are a number of clinical 
trials in progress dedicated to this approach, including, the 
identification of agents that bind specifically to VEGF ligands 
and those that directly target VEGF receptors.
Bevacizumab
Bevacizumab is a recombinant humanized IgG1 monoclonal 
antibody (MAb) with an approximate molecular weight of 
149 kD. It consists of approximately 93% human and 7% 
murine sequences.82 The antibody itself contains a human 
IgG1 framework region and the antigen–binding comple-
mentarity-determining regions of a murine antibody that 
binds to VEGF, Mab A.4.6.1. It selectively binds with high 
affinity (kd = 1.1 nM) and sterically inhibits all biologically 
active isoforms of human vascular endothelial growth factor 
to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on 
the surface of endothelial cells. By activating these recep-
tors downstream effects include tyrosine phosphorylation 
and induction of signal transduction pathways involved in 
mitogenesis and pro-survival activity within vascular endo-
thelial cells.82
Nonhuman safety and toxicology profile
To date there have been no studies assessing carcinogenicity or 
mutagenicity of bevacizumab. No studies have been conducted 
to investigate excretion in milk of lactating animals but excre-
tion of IgGs is expected to occur in breast milk. In nonclinical 
studies using Cynomolgus monkeys it was shown that beva-
cizumab may impair fertility and that this may be a reversible 
effect once it has been stopped.83 In addition, when administered 
at doses of 0.4 to 20 times the weekly human exposure, ana-
tomical pathology revealed several adverse effects on general 
growth and skeletal development, fertility and wound healing 
capacity. In rabbits that were treated with bevacizumab there 
was reduced wound healing capacity.83 Teratogenicity studies 
performed on pregnant rabbits demonstrated reduced or irregu-
lar ossification in the skull, jaw, spine, ribs, tibia and bones of 
the paws; meningocele; fontanel, rib and hindlimb deformities; 
corneal opacity; and absent hindlimb phalanges.
Pharmacokinetic profile of bevacizumab
The pharmacokinetic profile of bevacizumab was assessed in 
humans using an assay that measures total serum bevacizumab 
concentrations.84 Patients who received 1 to 20 mg/kg of OncoTargets and Therapy 2010:3 30
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bevacizumab weekly, every 2 weeks, or every 3 weeks, had 
an estimated half-life of bevacizumab of 20 days, with a range 
of 11 to 50 days and a predicted time to reach steady state of 
100 days. The clearance rate of bevacizumab was influenced 
by body weight, gender and tumor burden. After correcting 
for body weight, males had a higher bevacizumab clearance 
(0.262 L/day vs 0.207 L/day) and a larger Vc (3.25 L vs 
2.66 L) than females.84
Human safety profile
In the initial clinical studies that led to the FDA approval 
of bevacizumab in colon, breast, kidney and lung cancers 
the short-term toxicity of bevacizumab, alone or in combi-
nation with chemotherapy, was found to be acceptable.85–90 
Mild hypertension, manageable by medication, was the 
most common adverse event in addition to fatigue. A low 
frequency of more serious adverse events did occur, which 
included arterial thromboembolic events, congestive heart 
failure, bone marrow suppression, intracranial hemorrhage, 
impaired wound healing and gastrointestinal perforations. 
Toxicities may be potentiated by combining chemothera-
peutic agents with bevacizumab; examples of such adverse 
events include asthenia or fatigue, marrow suppression, 
neuropathy and liver dysfunction. One relatively uncom-
mon adverse event potentiated by such a regimen is the 
increased risk of congestive heart failure from 0.5% to 
2.2% in patients who have received prior or concomitant 
anthracyclines. As has been demonstrated in rabbit models 
bevacizumab impairs wound healing. In a controlled clini-
cal trial in patients with metastatic colorectal carcinoma 
who underwent surgery, the incidence of wound healing 
complications, including serious and fatal complications 
during the course of bevacizumab treatment was 15% and 
in those who did not receive bevacizumab, was 4%.87,88,89 
In the clinical trial setting, bevacizumab was administered 
until at least 28 days after surgery. The appropriate timing 
of when bevacizumab should be discontinued during the 
peri-surgical period has not been determined but should take 
into account the half-life of the drug which is about 21 days 
with a range of 11 to 50 days. Although there is a potential 
for immunogenicity no anti-bevacizumab antibodies have 
been detected thus far.
Bevacizumab and non-CNS  
solid tumors
Bevacizumab was the first anti-angiogenic inhibitor approved 
as an anti-tumor therapeutic agent. On February 26, 2004, 
the FDA approved bevacizumab as first-line treatment for 
patients with metastatic colorectal cancer. In a randomized-
double, blind-clinical trial of more than 800 patients with 
metastatic colorectal carcinoma, bevacizumab was compared 
to the standard chemotherapy of irinotecan, leucovorin 
(folinic acid) and fluorouracil (IFL). Patients who were 
given bevacizumab in combination with IFL survived about 
five months longer and the average time to tumor progres-
sion was four months longer than patients receiving IFL 
alone. The overall response rate to the treatment was 45% 
compared to 35% for the control arm of the trial.88,89 In June 
2006, bevacizumab was granted labeling extension for co-
administration with 5-fluoruracil-based chemotherapy for the 
treatment of metastatic colorectal carcinoma based on data 
from the E3200 trial. This trial was an open-label, random-
ized, three-arm, active-controlled, multi-center clinical trial 
in which bevacizumab alone was compared to bevacizumab 
plus FOLFOX4 (5-flourouracil, leucovorin, and oxaliplatin) 
and FOLFOX4 alone. There was a statistically significant 
improvement in overall survival (OS) in patients receiving 
bevacizumab plus FOLFOX4 compared to those receiving 
FOLFOX4 alone.87
Bevacizumab received FDA approval in October of 2006 
for a labeling extension for patients with unresectable, locally 
advanced, recurrent or metastatic nonsquamous, nonsmall 
cell lung carcinoma. This was based on the primary trial 
E4599, which was a randomized, active controlled, open 
label, multicenter clinical study evaluating bevacizumab plus 
carboplatin and paclitaxel versus carboplatin and paclitaxel 
alone. There was a statistically significant improvement in 
OS in those receiving bevacizumab with carboplatin and 
paclitaxel (median OS 12.3 vs 10.3 months; hazard ratio 
0.80, P = 0.013 stratified log rank test).85
An accelerated approval was granted in February 2008 for 
use in conjunction with paclitaxel in patients with metastatic 
HER-2 negative breast carcinoma in a single, open-label, 
randomized, multi-centre study E2100. While response rates 
were improved there was no improvement in disease-related 
symptoms nor increased OS.90 To date there are no data dem-
onstrating an improvement in disease-related symptoms or 
increased OS for breast cancer.
Most recently bevacizumab received FDA approval to 
be used in conjunction with interferon-alfa for patients with 
metastatic renal cell carcinoma who had undergone nephrec-
tomy. This was largely based on data from the BO17705 
trial, a randomized, double-blind, placebo-controlled, mul-
tinational clinical trial which demonstrated a median PFS 
of 10.2 months for the bevacizumab plus interferon arm 
compared to 5.4 months for the interferon and placebo arm OncoTargets and Therapy 2010:3 31
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(hazard ratio [HR], 0.60 (95% confidence interval [CI] 0.49 
to 0.72), P  0.0001).86 There was no statistically significant 
advantage in OS.86
Bevacizumab and recurrent 
malignant gliomas
A number of retrospective studies have been published 
documenting institution experiences with bevacizumab in 
patients with recurrent malignant glioma (MG) (Table 1). 
It is difficult to interpret data from these studies due to their 
retrospective nature. In addition, there often is no distinc-
tion between World Health Organization (WHO) grade III 
and IV tumors. These studies include a variety of com-
binations of chemotherapeutic agents such as irinotecan, 
TMZ and carboplatin. Response rates range between 11% 
to 79%, median progression-free survival (mPFS) from 
4.2 to 7.6 months and median overall survival (mOS) from 
4.6 to 12.6 months.91–96 Ali et al reported a case series 
of 13 patients with recurrent heavily pretreated malignant 
glioma treated with the combination of bevacizumab and 
irinotecan. Of the thirteen patients nine were started on beva-
cizumab at a dose of 5 mg/m2 every 2 weeks while the rest 
received a dose of 10 mg/m2; irinotecan was given at a dose of 
125 mg/m2 every week for 3 weeks. Of the 13 treated patients, 
10 (77%) had a radiographic partial response and 3 (23%) 
had stable disease. The median time to disease progression 
was 24 weeks while the mOS was 27 weeks.91 Narayana et al 
reported on 61 patients with recurrent high-grade gliomas 
treated with bevacizumab at 10 mg/kg every 2 weeks for 
4 doses in an 8-week cycle along with either irinotecan or 
carboplatin. At a median follow-up of 7.5 months (range 1 
to 19 months), 50 (82%) patients relapsed and 42 patients 
(70%) died of the disease. The mPFS and OS were 5 (95% CI 
2.3 to 7.7) and 9 (95% CI 7.6 to 10.4) months, respectively. 
Radiographic responses were noted in 73.6% of cases.92 
Norden et al in a retrospective study reviewed 55 consecutive 
Table 1 Selected trials of bevacizumab treatment in recurrent malignant glioma
Study Patients Regimen Response rate mPFS PFS-6 mOS
Ali et al91 13 MG (9) aB 5 mg/m2  
q2 wks (4) B 1 mg/m2 +  
i 125 mg/m2 q3 wks
10 (77%) mTTP 24 wks 27 wks
Friedman et al101 167 GBM (85)  





9.2 m  
8.7 m
Kang et al95 27 MG B + i 5.1 m 46% 12.6 m
Kreisl et al103 48 GBM B 10 mg/kg q2 wks 17 (35%) 16 wks (12–26) 29% (18–48) 31 wks (21–54)
Mohile et al105 10 GBM  
2 AG
B 10 mg/kg q2 wks + 
iMrT 6 Gy x5
7 (58%) 76%
Narayana et al92 37 GBM  
24 AG
B 10 mg/kg q2 wks +  
i 125 mg/m2 q2 wks  
or carboplatin AUC6 
q4 wks
39/54 (72%) 5 m (2.3–7.7) 9 m (7.6–10.4)
Nghiemphu et al96 44 GBM B 5 mg/kg q2 wks +  
various
4.25 m 41% 9.0 m
Norden et al97 33 GBM  
22 AG
B 10 mg/kg q2 wks +  
various
34.1% 23.9 wks  
(17.7–28.3)
42% GBM  
32% AG
35.7 wks (27.7–61.4)
Poulson et al93 27 GBM  
22 AG  
3 other
B 10 mg/kg +  
i q2 wks
30% GBM  
15% AG
22 wks 40% GBM  
33% AG
28 wks GBM  
32 wks AG
vrendenburgh et al98 35 GBM (23) B 10 mg/kg +  
i q2 wks  
(12) B 15 mg/kg  
q3 wks +  
i qwk 4/6 wks
20 (57% (39–74)) 24% (18–36) 46% (32–66) 42% (35–60)
Zuniga et al94 37 GBM  
14 AG
B 10 mg/kg + i 25/37 (68%) GBM 
11/14 (79%) AG
7.6 m GBM  
13.4 m AG
63.7% GBM  
78.6% AG
11.5 m GBM NA AG
aNumber of patients.
Abbreviations: AG, anaplastic gliomas; B, bevacizumab 10 mg/kg every 2 weeks; B + i, iriotecan 125–340 mg/m2 every 2 weeks; GBM, glioblastoma multiforme; iMrT, intensity 
modulated radiation therapy; MG, malignant glioma; mTTP, median time to tumor progression; m, months; NA, not available; PFS-6, 6-month progression-free survival; mOS, 
median overall survival; mPFS, median progression-free survical.OncoTargets and Therapy 2010:3 32
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patients with recurrent malignant gliomas who were treated 
with bevacizumab and chemotherapy (irinotecan, carboplatin, 
carmustine, temozolomide) to determine efficacy, toxicity, 
and patterns of recurrence. Only 2.3% of patients had a 
complete response, 31.8% had a partial response, 29.5% a 
minimal response, and 29.5% had stable disease. A PFS-6 
was 42% for patients with GBM and 32% for patients with 
anaplastic glioma.97 In a retrospective study by Zuniga et al 
of bevacizumab plus irinotecan in recurrent GBM, 6 (11.8%) 
of 51 patients discontinued treatment due to a treatment-
emergent adverse event, including one with end-stage renal 
failure and another with gastric perforation.94
There are several prospective trials of bevacizumab 
in recurrent GBM patients. The first study was published 
by Vredenburg et al.98 They reported on a phase II trial of 
35 patients divided into two treatment cohorts. The first 
cohort included 23 patients who received bevacizumab at 
10 mg/kg plus irinotecan every 2 weeks. The second cohort 
included 12 patients who were treated with bevacizumab 
15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 
29. The group reported 57% of patients achieving a partial 
response to therapy and a PFS-6 of 46% (95% CI 32% to 
66%). However, 11/35 (31%) patients discontinued therapy 
due to toxicity and an additional four withdrew due to fatigue. 
The results were an improvement when compared to historical 
controls which demonstrate a 6 month PFS of only 9% and 
response rates of 7% to 9%.22,99,100
Two pivotal trials have documented the bevacizumab 
monotherapy experience. This included the industry spon-
sored AVF3708g open-label, multi-center trial101 and a 
separate independent study, NCI 06-C-0064E, conducted at 
the National Cancer Institute.102 The AVF3708g open-label 
trial included a sample of 167 patients who were randomly 
assigned to receive bevacizumab alone or in combination with 
irinotecan 340 mg/m2 or 125 mg/m2 depending on the use 
of enzyme-inducing anti-seizure medications. The estimated 
PFS-6 rates were 42.6% (97.5% CI 29.6% to 55%) for the 
monotherapy group and 50.3% (97.5% CI 36.8% to 63.9%) 
for the combined group. While the study was not designed 
to be comparative, there was no statistically significant dif-
ference in survival between the two arms. Objective response 
rates were 28.2% (97.5% CI 18.5% to 40.3%) for the mono-
therapy group and 37.8% (97.5% CI 26.5% to 50.8%) for the 
combined group. The mOS rates were 9.2 months (97.5% CI 
8.2 to10.7 months) for the monotherapy group and 8.2 months 
(97.5% CI 7.8 to 10.9 months) for the combined group.
In the NCI trial, patients were treated with bevacizumab 
10 mg/kg every 2 weeks. Patients who progressed were 
offered participation in a companion study where irinotecan 
125 to 340 mg/m2 was immediately added to biweekly 
bevacizumab. None of the patients in the NCI trial who were 
subsequently treated with irinotecan had a response after 
progression on bevacizumab alone. A response rate of 35% 
and PFS6 29% (95% CI 18% to 48%) were documented in the 
first 48 of the 56 patients enrolled into this study. As a result 
of the data obtained in these trials, bevacizumab received an 
accelerated FDA approval in May 2009 as monotherapy in 
patients with GBM who progressed after initial treatment.
The utility of irinotecan in combination with bevacizumab 
has not been established. This is of little surprise since single 
agent irinotecan in glioma patients has shown little efficacy 
in previous studies.103,104 To date, no other standard therapy 
has proven itself to be superior to other treatments when 
combined with bevacizumab for the treatment of recurrent 
GBM. As such, various other combinations of bevacizumab 
have been attempted. Mohile et al reported on a small group 
of 12 patients who achieved a 58% response rate and a PFS-6 
of 76% with fractionated focal radiotherapy on small volume 
tumors.105 In an attempt to answer the question of whether the 
addition of cytotoxic agents may have a synergistic effect, 
various groups have reviewed their experience with bevaci-
zumab in combination with agents such as TMZ, irinotecan, 
carboplatin, nitrosureas, etoposide and erlotinib. In a group 
of 54 patients treated with irinotecan versus 7 patients treated 
with carboplatin in combination with bevacizumab no sig-
nificant difference in survival was documented.92
Based on the NCI trial that led to the FDA approval for 
bevacizumab in recurrent GBM, patients overall tolerated 
monotherapy well.102 The most frequently observed severe 
adverse event possibly or probably related to bevacizumab 
in 48 treated patients was the occurrence of thromboem-
bolic events which occurred in six patients (12.5%). One 
patient experienced a stroke and the other three experienced 
a pulmonary embolus. None of the patients experienced an 
intracranial hemorrhage. Hypertension was the second most 
frequent drug-related adverse event that was easily treated 
with antihypertensive medication. Six patients (12.5%) 
were removed from the study for drug-associated toxicity 
that included five thromboembolic events, and one bowel 
perforation. Grade 1 proteinuria was reported in one patient 
and Grade 3 hepatic dysfunction was reported in one patient 
as well. Grade 2 and 3 thrombocytopenia was observed in 1 
and 2 patients respectively.
In the AVF3708G trial,101 98.8 % of patients in the 
bevacizumab alone arm experienced adverse events with 
the most common being fatigue (45.2%), headache (36.9%), OncoTargets and Therapy 2010:3 33
Bevacizumab for glioblastoma treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
hypertension (29.8%), diarrhea (21.4%) and epistaxis (19%). 
Adverse events took place in all patients in the irinotecan 
and bevacizumab arm with the most common being fatigue 
(75.9%), diarrhea (74.7%), nausea (67.1%) and constipa-
tion (40.5%). Grade 3 or higher treatment emergent AEs 
occurred in 46.4% of bevacizumab recipients and 65.8% 
of bevacizumab plus irinotecan recipients. Selected AEs 
associated with bevacizumab treatment included arterial 
thromboembolism (grade  3; bevacizumab, 2.4%; in the 
irinotecan group, 2.5%), venous thromboembolism (bevaci-
zumab, 3.6%; combined group, 8.9%), and wound-healing 
complications. Two patients (2.5%) experienced grade 3 
gastrointestinal perforation and one patient (1.3%) expe-
rienced serious reversible posterior leukoencephalopathy 
syndrome in the combined group. A grade 1 intracranial 
hemorrhage was noted in two patients (2.4%) who received 
only bevacizumab versus 3 patients in the combined group 
(3.8%) experiencing a grade 1, 2 and 4 respectively. AEs 
led to bevacizumab discontinuation for four patients (4.8%) 
in the bevacizumab arm and for 14 patients (17.7%) in the 
irinotecan group. Two patients in the bevacizumab arm 
died secondary to neutropenia and pulmonary embolism 
while one reportedly died of a seizure within the com-
bined group.
Newly diagnosed malignant gliomas
A number of investigators are conducting upfront studies 
for newly diagnosed GBM since survival benefit data for 
recurrent disease with the use of bevacizumab have not 
been established and will not likely be an end-point in future 
trials for recurrent disease. Nicholas et al reported a study of 
bevacizumab added to adjuvant TMZ after concurrent chemo-
radiation.106 Preliminary results from 42 of 48 enrolled 
patients demonstrated complete radiographic responses in 
5/42 (12%) patients, a partial response in 9 (21%), 13 (31%) 
were stable and 7 (17%) showed progressive disease.
Lai et al reported a phase II trial of 70 patients treated 
with focal external beam radiation (60 Gy in 30 fractions), 
biweekly bevacizumab 10 mg/kg and daily TMZ 75 mg/m2. 
After a two week post-radiation interval, combination therapy 
with biweekly bevacizumab and monthly TMZ was given. All 
but 2 patients had total or partial resections. Median follow-up 
was 17.2 months and 50% of the group had a Kamovsky Per-
formance Scale of 60% to 80%. Median PFS was 13 months 
(95% CI 11.3 to 15.9 months) and PFS-6 was 89.1% (95% CI 
78.6 to 94.7 months) compared to 8.1 months (95% CI 7.0 
to 11.7 months) and 64.4% (95% CI 54.5 to 72.7 months) 
for an internal control group. Median OS was 25 months 
(95% CI 16.1 to NA) compared to 21.1 months in the control 
group. In the treatment group, 6- and 18-month OS was 98.6% 
(95% CI 90.2 to 99.8 months) and 61.1% (95% CI 45.9 to 73.3 
months), respectively, compared to 88.2% (95% CI 80.5 to 
93 months) and 60.6% (95% CI 50.8 to 69.1 months) in the 
control group. Unexpected adverse events included isolated 
cases of retinal detachment and optic neuropathy.107 The most 
common treatment related serious adverse effects included 
thrombotic complications with 12 (17%) patients being 
diagnosed with deep vein thrombosis. Hypertension was 
reported in 8 (11%) patients. Four (6%) patients had wound 
related infections involving their craniotomy sites. Other 
adverse events included involvement of the gastrointestinal 
and renal systems. Neurological events included seizures in 
5 (7%) patients, transient ischemic attack/stroke in 3 patients 
and 1 patient with a traumatic hemorrhage.107
A similarly designed study of 15 patients was reported 
by Narayana et al with 1-year PFS and OS being 59.3% and 
86.7% respectively.108 Radiographic responses were noted in 
13 of 14 assessable patients (92.8%). Gruber et al utilized a 
more dose intense schedule of adjuvant TMZ with bevaci-
zumab for newly diagnosed GBM. The PFS-6 survival was 
77.5%, the median PFS was 17 months, while the 1- and 
2-year OS was 83% and 57%, respectively.109
Two ongoing randomized phase III trials will investigate 
the efficacy and safety of adding bevacizumab to standard 
upfront chemoradiation with temozolomide. A phase III, 
double-blind, placebo controlled trial (Radiation Therapy 
Oncology Group 0825) has a target accrual of 720 patients. 
Patients with newly diagnosed GBM will undergo 3 weeks 
of standard chemoradiation and in addition will undergo 
analysis for MGMT promoter methylation and molecular 
profiling. Patients will then be stratified into two arms for 
the final 3 weeks of chemoradiation. The first arm will 
receive concurrent placebo while the second arm will receive 
biweekly bevacizumab. This will be followed by adjuvant 
treatment in which the first arm will continue with placebo 
in addition to TMZ and the second arm will receive TMZ 
with biweekly bevacizumab.110 The other phase III trial is 
an industry sponsored randomized, double-blind, placebo-
controlled trial with an expected target accrual of over 
500 patients. In this trial patients will be randomly assigned 
to either bevacizumab or the placebo arm, in combination 
with standard radiation therapy plus temozolomide for 6 
weeks. After a 4 week hiatus, patients will continue to receive 
bevacizumab or placebo, plus adjuvant temozolomide for 
6 cycles of maintenance therapy. Bevacizumab or placebo 
monotherapy will then continue until disease progression.111 OncoTargets and Therapy 2010:3 34
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As yet, the role of bevacizumab in the upfront management 
of GBM remains to be determined.
Bevacizumab and its clinical benefit
The effects of bevacizumab on vascular permeability are akin 
to the effects of steroids on cerebral edema.112 We, therefore, 
have at our disposal another drug other than dexamethasone 
that can produce improvement of neurological signs and 
symptoms, which can translate into improved quality of 
life.112 This was demonstrated in the two trials that led to the 
FDA approval of bevacizumab in recurrent GBM. In the NCI 
trial, 50% patients had decreased cerebral edema. Approxi-
mately 58% of patients on steroids at the start of treatment 
were able to achieve an average dose reduction of 59% and 
52% had improved neurological symptoms.102 Findings were 
similar in the industry sponsored trial which also assessed 
cognitive function. The majority of patients demonstrated 
stable performance on a variety of tests at the six week 
follow-up and 18% to 25% had improved performance.113 
Bevacizumab clearly has a role in the treatment of patients 
with GBM, independent of survival benefit, for its steroid-
sparing effect.
The dramatic effects of bevacizumab on the MRI contrast 
signal (Figure 1) is at least partially a result of its effect on 
vascular permeability since reduction in enhancement can be 
observed with just one dose of the drug; too short of an interval 
for true tumorcidal activity. Consequently, MRI contrast signal 
may not be a reliable proxy marker for extent of tumor as it 
is for evaluating cytotoxic therapy. For this reason alterna-
tive imaging methods are being investigated to assess tumor 
response such as dynamic susceptibility contrast enhanced 
MRI and apparent diffusion coefficient measures.114–116
Despite the beneficial effect of bevacizumab, concern has 
arisen that it may actually influence the pattern of disease 
progression and thereby promote tumor invasion. This was 
observed in both in vitro and in vivo studies which dem-
onstrated the up-regulation of invasion related genes such 
as MMP 9 or other pro-angiogenic factors.117 The pattern 
of relapse, prognosis and outcome of further therapy in 
patients who failed bevacizumab was recently described in 
an institutional review. Iwamoto et al reported a series of 
37 patients with recurrent GBM who progressed on treatment 
with bevacizumab. The mOS after progression on bevaci-
zumab was 4.5 months. Seventeen patients (46%) had local 
recurrence and 6 (16%) had multifocal recurrence. Thirteen 
patients (35%) had non-enhancing disease progression. The 
patients with non-enhancing tumor did worse with shorter 
survival, which was thought to be due to a larger disease 
burden impacting negatively on performance status. Non-
enhancing tumor was also thought to be an independent 
Figure 1. A) Axial T1-weighted, post-contrast image of the brain in a patient with glioblastoma multiforme who progressed on temozolomide therapy. B) response after 
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prognostic factor.118 Similar findings were reported by Zuniga 
et al but others have reported lower rates of infiltrative dis-
ease on the order of 20% to 30%.92,120 It is difficult to discern 
whether anti-VEGF therapy actually accelerates or promotes 
tumor invasion or whether the natural course of the disease is 
altered so that patients are alive long enough for us to observe 
this degree of tumor progression, unmasked by the effect 
bevacizumab has on gadolinium enhancement. It is clear that 
clinical trials that are using anti-VEGF therapy will need to 
measure response using methods that incorporate evaluation 
of non-enhancing disease.
While bevacizumab appears to be an effective agent 
for recurrent GBM, the majority of patients do not achieve 
durable disease control and other salvage regimens are 
required. Often, adding a cytotoxic agent or switching the 
companion cytotoxic agent is attempted, but efficacy of this 
practice is unclear. Quant et al described a retrospective 
review of 54 patients with recurrent MG who progressed on 
either bevacizumab mono- or combination therapy who were 
then subsequently treated with an alternate bevacizumab-
containing regimen.119 Tumor progression was determined 
clinically and radiographically. The median prior chemo-
therapy regimens including the first bevacizumab-containing 
regimen was 3 (range, 2 to 5). The mPFS on the first 
bevacizumab-containing regimen was 124 days (95% CI 
87 to 154 days); PFS-6 was 33% and the mPFS on the second 
bevacizumab-containing regimen was 37.5 days (95% CI 
34 to 42 days) with a PFS-6 of 2%. In the review by Iwamoto 
et al 19 of the 37 patients received salvage chemotherapy after 
failure with bevacizumab. The mOS in those who received 
salvage treatment was 5.2 months and the PFS-6 was 0%. 
It is clear that other therapeutic options need to be consid-
ered for such patients.118
Conclusion
Tumor angiogenesis has emerged as a valid therapeutic target 
in clinical oncology and the VEGF system represents a key 
mediator in this process. While monotherapy with bevaci-
zumab for recurrent GBM has afforded encouraging results, 
it by no means approaches a cure or durable disease control 
for the majority of patients. Continued efforts are needed 
to improve on this early success. Rational combinations of 
targeted therapy with bevacizumab are appropriately being 
studied, as well as bevacizumab’s role in the upfront treatment 
of glioma patients. The post-bevacizumab era will prove to 
be a challenging environment for the neuro-oncology com-
munity in evaluating new salvage therapy, but one that for 
the first time may carry real promise.
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